Bilateral Retinal Vasculitis as Initial Presentation of Systemic Lupus Erythematosus with Secondary Antiphospholipid Syndrome.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
medline:
29
11
2023
pubmed:
28
11
2023
entrez:
28
11
2023
Statut:
epublish
Résumé
BACKGROUND Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of undefined etiology with a relapsing and remitting course. Lupus retinopathy is reported in around 10% of patients with SLE; however, it is rarely the initial presenting feature of the disease. We report a unique case of bilateral retinal vasculitis as the initial presentation of SLE with secondary antiphospholipid syndrome (APS). CASE REPORT A 34-year-old man, previously healthy, presented to the eye clinic for the first time with painless reduced vision for 3 weeks. A review of systems revealed generalized fatigue, myalgia, arthralgias, and weight loss of around 10 kg in the last 3 months. On ophthalmic examination, his visual acuity was reduced bilaterally, more in the right eye. A fundus exam revealed bilateral diffuse multiple cotton-wool spots, dot and blot hemorrhage covering the posterior pole, and venous congestion and beading. In addition, there was cystoid macular edema (CME) in the fovea of both eyes, and fundus fluorescein angiography (FFA) showed bilateral areas of peripheral and macular hypo-fluorescence, multiple hyper-fluorescent knob-like aneurysmal dilatations, and vascular leaking and staining. He was diagnosed with SLE by the rheumatology team based on the clinical presentations and laboratory investigations. The patient was managed with intravenous methylprednisolone and discharged on oral prednisone with a tapering regimen. Eighteen months after, he reported significant improvement in his vision with regular follow-ups. CONCLUSIONS Ocular manifestations can be the initial presentation of SLE and can lead to serious ocular complications. Early diagnosis and proper management are essential and require cooperation between rheumatologists and ophthalmologists.
Identifiants
pubmed: 38013402
pii: 942085
doi: 10.12659/AJCR.942085
pmc: PMC10697493
doi:
Substances chimiques
Methylprednisolone
X4W7ZR7023
Types de publication
Case Reports
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e942085Références
J Fr Ophtalmol. 2017 Nov;40(9):793-800
pubmed: 29054477
Rheumatol Int. 2023 Oct;43(10):1947-1956
pubmed: 37318546
J Fr Ophtalmol. 2023 Oct;46(8):961-965
pubmed: 37558521
Med J Malaysia. 2002 Dec;57(4):490-2
pubmed: 12733176
Rheumatol Int. 2018 Aug;38(8):1495-1501
pubmed: 29948002
Cureus. 2022 Sep 21;14(9):e29432
pubmed: 36312628
J Indian Med Assoc. 2006 Sep;104(9):526-7
pubmed: 17388013
Indian J Ophthalmol. 2018 Sep;66(9):1317-1319
pubmed: 30127152
Lupus. 2017 Apr;26(5):522-528
pubmed: 28394224
Clin Exp Ophthalmol. 2004 Feb;32(1):87-100
pubmed: 14746601
Arq Bras Oftalmol. 2021 Jul-Aug;84(4):395-401
pubmed: 34287516
Ophthalmology. 2003 Jul;110(7):1321-6
pubmed: 12867385
Am J Case Rep. 2021 May 03;22:e930650
pubmed: 33935278
Int J Mol Sci. 2022 Oct 14;23(20):
pubmed: 36293119
BMC Ophthalmol. 2022 Nov 14;22(1):434
pubmed: 36376841
Semin Arthritis Rheum. 1999 Apr;28(5):326-32
pubmed: 10342390